New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

ABSTRACT:

Background

Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited risk-benefit ratio of vitamin K antagonists, pharmacological research has been directed towards the development of products that could overcome these limits, new oral anticoagulants were recently introduced: dabigatran, rivaroxaban, apixaban, and edoxaban.

Aim

Scope of the present study was to examine patterns of use, effectiveness, safety and mean annual cost per patient of anticoagulant treatment for non-valvular AF in real clinical practice.

Methods

A retrospective observational cohort study, by using administrative databases (drugs, hospitalizations, clinical visits, lab tests, populati

SUBMITTER: Bellin A 

PROVIDER: S-EPMC6779249 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature